Small intestine cancer

Jump to navigation Jump to search


For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Parminder Dhingra, M.D. [3]

Small intestine cancer Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Small intestine cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Small intestine cancer On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Small intestine cancer

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Small intestine cancer

CDC on Small intestine cancer

Small intestine cancer in the news

Blogs on Small intestine cancer

Directions to Hospitals Treating Small intestine cancer

Risk calculators and risk factors for Small intestine cancer

Synonyms and keywords:

Historical Perspective

Despite of

Classification

Intestinal cancers can be classified into:[1]

  • Benign tumors
  • Malignant tumors
  • Extra-intestinal tumors.
Tumors Types
Benign Tumors 1- Leiomyoma

2-Lipoma

3-Hamartoma

4-Desmoid tumors

Malignant Tumors 1-Adenocarcinoma

2-Leiomyosarcoma

3-Carcinoid tumors

4-Neuroendocrine tumors

5-Lymphomas

Extra- Intestinal Tumors Metastasis to small intestine is mostly through:

1-Contagious spread (uncommon, mostly route of spread for Melanoma)

2-Peritoneal spread

Pathophysiology

  • Pathophysiology of the small intestinal cancers is not much studied domain, as it is a rare condition.
  • Studies are being conducted to evaluate association with environmental risk factors. [2]
  • Low susceptibility of the small intestine to malignant change can be explained by following:
    • Short exposure of the mucosa to carcinogens due to rapid transit of contents.
    • Liquid nature of the contents and less mucosal irritation.
    • Low bacterial load
    • High concentration of lymphoid tissue
Associations:
  • Cancer of small intestine can arise sporadically or they are associated with genetic diseases.
  • Pathophysiology of small intestinal cancers depend on the histological subtype.
  • Duodenal tumors are more common than the tumors of jejunum and illeum.[3]
  • Adenomas arise more proximally in the duodenum and lymphomas arise in jejunum and ileum.[4]
  • Inflammatory disorders predispose to malignancy. Some of the associations are:[1]

Adenocarcinoma:

  • Adenocarcinoma of the smalls intestine originate locally or can be associated with malignant tumors of other sites.
  • Rarely people with Peutz-Jeghers syndrome can develop malignant changes in polyps present in the small intestine.
  • Primary adenocarcinoma consists of 40% of cases of malignant tumors of small intestine and it is the most common histologic type. [5]
  • Adenocarcinomas can be polypoid, infiltrating, or as annular constricting lesions is small intestine. Polyps and adenomas of small intestine are considered precursor lesions of adenocarcinoma.[6]


Adenocarcinoma of the small intestine. Endoscopic image of adenocarcinoma of duodenum. Source: Wikimedia commons

Neuroendocrine tumors:

  • Small Intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumors.[7]
  • They are diverse neoplasms emerging from the endocrine cells of the intestinal mucosa.[8]
  • These tumors originate from enterochromaffin (EC) cells and secrete serotonin.[9]
  • The oncofetal protein IMP3 is a marker that plays a role in the growth of neuroendocrine cells and its expression is associated with prognostic value in neuroendocrine tumors.[8]
Typical histological appearance of neuroendocrine carcinoma, showing neuroednocrine tumor cells(bottom), Paneth cells(red cells at the base of the crypt) and intestinal villi.Source: Wikimedia Commons

Carcinoid tumors:

  • Carcinoid tumors are the second most common cancer of the small intestine.
  • It is a slow growing tumor of small intestine arising as a subset of neuroendocrine cells.
  • Carcinoid tumors of the smalls intestine are mostly associated with malignant tumors of the other sites. [5]
Carcinoid tumor of small intestine invading plica circularisSource: Wikimedia commons
Multiple Carcinoid tumor of the small intestine Source: Wikimedia commons

Non-Hodgkin Lymphoma:

  • After stomach, small intestine is the most common extra-nodal site of presentation of non-Hodgkin lymphomas and it represents 4% to 20% of all the non-Hodgkin lymphomas.
  • Some of the association of non-Hodgkin lymphomas are :[10]
    • Helicobacter pylori infection
    • Immunosuppression after solid-organ transplantation
    • Celiac disease
    • Inflammatory bowel disease
    • Human immunodeficiency virus (HIV)
  • Small intestinal lymphomas are of low-grade histology and arise from mucosal-associated lymphoid tissues (MALT) present in ileum and jejunum.Sometimies distinct clinicopathologic entities arise from these mucosal-associated lymphoid tissues (MALT), such as immunoproliferative small intestinal disease, primary intestinal T-cell lymphoma and multiple lymphomatous polyposis.[10]

Small intestinal stromal tumors (GISTs):

  • Gastrointestinal stromal tumors (GISTs) are the most common benign tumors of the gastrointestinal (GI) tract.
  • GISTs typically develop in older age. Stromal tumors are most common in the stomach, 60–70% of the stromal tumors, followed by small intestine which makes 20–25% of all the stromal tumors of GI tract, colon and rectum makes 5% and esophagus is less than 5%. GISTs are mostly benign tumors and rarely can be malignant.
  • Instestinal stromal cell tumors should be differentiated from leiomyosarcomas and leiomyomas. They differ clinically and pathogenetically from leiomyosarcomas and leiomyomas. Leimyomas occur in the GI tract, commonly in the esophagus.
Gastrointestinal stromal tumor in the jejunum, endoscopic image.Wikimedia commons
  • One of the subset of intestinal stromal cell tumors is the GI autonomic nerve tumors (GANTs). Stromal tumors can be differentiated from other tumors of small intestine by their cell specific markers.
  • GISTs express following stromal cell markers:[11]
    • 70% of GISTs are positive for CD34
    • 20–30% are positive for smooth muscle actin (SMA)
    • 10% are positive for S100 protein
    • <5% are positive for desmin

Etiology

  • Some genetic syndromes are associated with small intestine cancers. Intestinal cancer caused by the genetic syndrome in the presence of a family history, are diagnosed at a younger age than sporadic tumors.
  • Single nucleotide mutations, either on the same chromosome or on different chromosomes are considered to be associated with such cancer-associated genetic syndromes. Small intestinal cancers can be sporadic.[12]
  • According to some studies done in Europe and United States, tobacco, alcohol and obesity are considered to play a role in the etiology of small intestine cancers.[13]

Epidemiology and Demographics

  • Small intestinal cancer makes less than two percent of the gastrointestinal track cancers.[14]
  • Incidence has increased recently particularly in African American males and it is unchanged for the females.[2]
  • Age adjusted incidence rates were 1.2/100,000 inhabitants for men and 0.8/100,000 inhabitants for women shown by a study done in 2006.[15]
  • According to a study done among 498,376 men and women in 2014, the age standardized incidence rates for small intestinal cancers were 5.5 and 4.8 per 100,000 person-years for men and women, respectively. For the histologic subtypes, the incidence rates per 100,000 person-years were 2.2 and 1.3 for adenocarcinomas, and 2.6 and 2.9 for carcinoids, for men and women, respectively.[16]

Risk Factors

Screening

  • Currently there are no screening protocols and rarity of condition makes it a less suspected condition.[18]

Natural History, Complications, and Prognosis

  • Clinical features and natural history of small intestinal tumors have not been clearly studied, as its a rare condition.[19]
  • Adenocarcinoma of the duodenum is associated with low overall survival rate compared to the tumors located in Jejunum and ileum.[3]

Diagnosis

  • Adenocarcinoma of the small intestine is usually diagnosed late and patients present with metastasis of lymph node or distant sites.
  • Small intestinal cancers are not suspected clinically as their incidence is very low.
  • Endoscopy, ultrasound and barium examination, all are the first-line studies for nonspecific intestinal symptoms.
  • Inaccessibility of endoscope to the small intestine can be the cause of their late diagnosis but with the advent of eneteroscope distant parts of intestine can be accessed.[18]

History and Symptoms

Physical Examination

  • Clinical features of small intestinal tumors have not been clearly studied, as its a rare condition.[19]
  • Advanced stage tumors present with signs of intestinal obstructions.

Ultrasonography

  • Ultrasonography can provide useful information in the diagnosis as small intestinal tumors have typical ultrasonographic features.

CT scan

  • CT can help in differenting the small intestinal cancers. Different tumors have different appearance on CT:[20]
  • In Peutz-Jeghers Syndrome, non-neoplastic lesions may resemble small intestinal neoplasm on CT.
Tumors Findings on CT
Adenocarcinmoa Ulcerative lesions, nodular lesions and annular lesions
Carcinoid tumors Poorly defined homogenous mass displacing intestinal loops

Calcification and desmoplastic reaction is a very specific finding of Carcinoid tumors on CT

Non-Hodgkin lymphoma Bulky mass on CT

Lymphoma is associated with significant dilation of the lumen of intestine

Gastrointestinal stromal tumors(GISTs) Intraluminal, subserosal or submucosal homogeneous masses with sharply defined borders

Calcifications

Lipoma Intraluminal homogeneous mass, well-circumscribed and with some fat attenuation
Malignant metastasized tumors Intraperitoneal seedings extending locally

Metastasized tumors give appearance of multiple small nodular masses in intestinal serosa, mesentery and omentum.

MRI

Biopsy

  • MRI, CT and Ultrasound are reliable screening and diagnostic techniques for the identification and staging of small intestinal tumors but diagnosis of cancer can only be confirmed by the histopathology analysis. So, Biopsy is the diagnostic study of choice.[21]

Treatment

Medical Treatment

Surgical Treatment

Radiotherapy

Chemotherapy

Prevention

Primary Prevention

  • There are no established measures for the primary prevention of small intestinal cancers.

Secondary Prevention

References

  1. 1.0 1.1 Gill SS, Heuman DM, Mihas AA (October 2001). "Small intestinal neoplasms". J. Clin. Gastroenterol. 33 (4): 267–82. PMID 11588539.
  2. 2.0 2.1 Severson RK, Schenk M, Gurney JG, Weiss LK, Demers RY (February 1996). "Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults". Cancer Epidemiol. Biomarkers Prev. 5 (2): 81–4. PMID 8850266.
  3. 3.0 3.1 3.2 Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (August 2004). "Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients". Cancer. 101 (3): 518–26. doi:10.1002/cncr.20404. PMID 15274064.
  4. Chow JS, Chen CC, Ahsan H, Neugut AI (August 1996). "A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990". Int J Epidemiol. 25 (4): 722–8. PMID 8921448.
  5. 5.0 5.1 Barclay TH, Schapira DV (March 1983). "Malignant tumors of the small intestine". Cancer. 51 (5): 878–81. PMID 6821853.
  6. Levine JS, Ahnen DJ (December 2006). "Clinical practice. Adenomatous polyps of the colon". N. Engl. J. Med. 355 (24): 2551–7. doi:10.1056/NEJMcp063038. PMID 17167138.
  7. Modlin, Irvin M.; Champaneria, Manish C.; Chan, Anthony K.C.; Kidd, Mark (2007). "A Three-Decade Analysis of 3,911 Small Intestinal Neuroendocrine Tumors: The Rapid Pace of No Progress". The American Journal of Gastroenterology. 102 (7): 1464–1473. doi:10.1111/j.1572-0241.2007.01185.x. ISSN 0002-9270.
  8. 8.0 8.1 Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D, Pellegrinelli A, Milione M, Ferrero S (November 2017). "IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence". Endocrine. 58 (2): 360–367. doi:10.1007/s12020-017-1249-x. PMID 28210937.
  9. Sei Y, Feng J, Zhao X, Forbes J, Tang D, Nagashima K, Hanson J, Quezado MM, Hughes MS, Wank SA (July 2016). "Polyclonal Crypt Genesis and Development of Familial Small Intestinal Neuroendocrine Tumors". Gastroenterology. 151 (1): 140–51. doi:10.1053/j.gastro.2016.03.007. PMC 5578471. PMID 27003604.
  10. 10.0 10.1 Crump M, Gospodarowicz M, Shepherd FA (June 1999). "Lymphoma of the gastrointestinal tract". Semin. Oncol. 26 (3): 324–37. PMID 10375089.
  11. Schlotzhauer WS, Chortyk OT, Austin PR (1976). "Pyrolysis of chitin, a potential tobacco extender". J Agric Food Chem. 24 (1): 177–80. PMID 1432-2307 Check |pmid= value (help).
  12. Jass JR (December 2007). "Gastrointestinal polyposes: clinical, pathological and molecular features". Gastroenterol. Clin. North Am. 36 (4): 927–46, viii. doi:10.1016/j.gtc.2007.08.009. PMID 17996798.
  13. Boffetta P, Hazelton WD, Chen Y, Sinha R, Inoue M, Gao YT, Koh WP, Shu XO, Grant EJ, Tsuji I, Nishino Y, You SL, Yoo KY, Yuan JM, Kim J, Tsugane S, Yang G, Wang R, Xiang YB, Ozasa K, Nagai M, Kakizaki M, Chen CJ, Park SK, Shin A, Ahsan H, Qu CX, Lee JE, Thornquist M, Rolland B, Feng Z, Zheng W, Potter JD (July 2012). "Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium". Ann. Oncol. 23 (7): 1894–8. doi:10.1093/annonc/mdr562. PMC 3493138. PMID 22147734.
  14. North JH, Pack MS (January 2000). "Malignant tumors of the small intestine: a review of 144 cases". Am Surg. 66 (1): 46–51. PMID 10651347.
  15. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J (December 2006). "Incidence and management of primary malignant small bowel cancers: a well-defined French population study". Am. J. Gastroenterol. 101 (12): 2826–32. doi:10.1111/j.1572-0241.2006.00854.x. PMID 17026561.
  16. Miller RR, Menke JA, Hansen NB, Zwick DL, Bickers RG, Nowicki PT (August 1986). "The effect of naloxone on the hemodynamics of the newborn piglet with septic shock". Pediatr. Res. 20 (8): 707–10. doi:10.1203/00006450-198608000-00001. PMID 3737280.
  17. Sarosiek T, Stelmaszuk M (February 2018). "[Small intestine neoplasms]". Pol. Merkur. Lekarski (in Polish). 44 (260): 45–48. PMID 29498365.
  18. 18.0 18.1 Rossini FP, Risio M, Pennazio M (January 1999). "Small bowel tumors and polyposis syndromes". Gastrointest. Endosc. Clin. N. Am. 9 (1): 93–114. PMID 9834319.
  19. 19.0 19.1 Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T (August 2010). "Clinical features of and chemotherapy for cancer of the small intestine". Anticancer Res. 30 (8): 3193–7. PMID 20871040.
  20. Buckley, J A; Fishman, E K (1998). "CT evaluation of small bowel neoplasms: spectrum of disease". RadioGraphics. 18 (2): 379–392. doi:10.1148/radiographics.18.2.9536485. ISSN 0271-5333.
  21. Tanzer J, Lessard M, Guilhot F, Brizard A (1987). "[Rearrangement of the short arm of chromosome 12 in chronic myelomonocytic leukemias]". Nouv Rev Fr Hematol (in French). 29 (1): 65–8. PMID 3473441.


Template:WikiDoc Sources